Trial Profile

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etrumadenant (Primary) ; Quemliclustat (Primary) ; Zimberelimab (Primary) ; Docetaxel; Enzalutamide; Sacituzumab govitecan
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ARC-6
Sponsors Arcus Biosciences

Most Recent Events

11 Sep 2024 Status changed from active, no longer recruiting to completed.
06 Feb 2024 Planned End Date changed from 1 Apr 2024 to 1 Aug 2024.
06 Feb 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com